| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.843 | 0.002 | 0.843 | Anesthetic general | 0.434 0.013 DBMET00330 | ||
| 0.706 | 0.014 | 0.706 | Cyclophilin D inhibitor | 0.573 0.032 DBMET00330 | ||
| 0.621 | 0.004 | 0.621 | Anesthetic local | |||
| 0.548 | 0.002 | 0.548 | MAP3K7 inhibitor | |||
| 0.374 | 0.01 | 0.374 | Protein-tyrosine phosphatase inhibitor | 0.133 0.098 DBMET00330 | ||
| 0.338 | 0.004 | 0.338 | Phosphodiesterase 4A inhibitor | |||
| 0.342 | 0.056 | 0.395 | Calcium channel activator | 0.395 0.026 DBMET00330 | DBMET00330 | |
| 0.268 | 0.006 | 0.268 | Phosphodiesterase 4D inhibitor | |||
| 0.21 | 0.008 | 0.21 | Sphingosine 1-phosphate receptor 5 antagonist | 0.206 0.009 DBMET00330 | ||
| 0.195 | 0.009 | 0.195 | Sphingosine 1-phosphate receptor 2 antagonist | 0.182 0.014 DBMET00330 | ||
| 0.216 | 0.03 | 0.753 | Alpha-N-acetylglucosaminidase inhibitor | 0.753 0.003 DBMET00330 | DBMET00330 | |
| 0.339 | 0.163 | 0.477 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.477 0.045 DBMET00330 | DBMET00330 | |
| 0.291 | 0.122 | 0.505 | GABA C receptor rho-3 antagonist | 0.505 0.025 DBMET00330 | DBMET00330 | |
| 0.17 | 0.007 | 0.17 | Janus tyrosine kinase 1 inhibitor | |||
| 0.177 | 0.016 | 0.177 | Sphingosine 1-phosphate receptor 4 antagonist | 0.167 0.021 DBMET00330 | ||
| 0.155 | 0.001 | 0.155 | Glucose-dependent insulinotropic receptor antagonist | |||
| 0.17 | 0.047 | 0.182 | CF transmembrane conductance regulator agonist | 0.182 0.035 DBMET00330 | DBMET00330 | |
| 0.152 | 0.037 | 0.198 | Ca2+-transporting ATPase inhibitor | 0.198 0.004 DBMET00330 | DBMET00330 | |
| 0.137 | 0.04 | 0.637 | GABA C receptor agonist | 0.637 0.002 DBMET00330 | DBMET00330 | |
| 0.139 | 0.05 | 0.139 | Protein-tyrosine phosphatase 1B inhibitor | 0.1 0.078 DBMET00330 | ||
| 0.134 | 0.054 | 0.134 | Beta amyloid protein antagonist | 0.134 0.053 DBMET00330 | ||
| 0.089 | 0.012 | 0.089 | Sphingosine 1-phosphate receptor 3 antagonist | 0.073 0.023 DBMET00330 | ||
| 0.107 | 0.04 | 0.107 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | |||
| 0.178 | 0.111 | 0.189 | 5 Hydroxytryptamine 3E antagonist | 0.189 0.084 DBMET00330 | DBMET00330 | |
| 0.158 | 0.098 | 0.389 | Succinate dehydrogenase inhibitor | 0.389 0.004 DBMET00330 | DBMET00330 | |
| 0.204 | 0.145 | 0.401 | 5 Hydroxytryptamine uptake stimulant | 0.401 0.014 DBMET00330 | DBMET00330 | |
| 0.096 | 0.038 | 0.096 | Janus tyrosine kinase 2 inhibitor | |||
| 0.197 | 0.14 | 0.421 | Tyrosine 3 hydroxylase inhibitor | 0.421 0.006 DBMET00330 | DBMET00330 | |
| 0.141 | 0.085 | 0.201 | Phospholipase A2 inhibitor | 0.201 0.042 DBMET00330 | DBMET00330 | |
| 0.059 | 0.006 | 0.059 | Cathepsin F inhibitor | 0.045 0.02 DBMET00330 | ||
| 0.107 | 0.054 | 0.287 | UDP-glucose 4-epimerase inhibitor | 0.287 0.011 DBMET00330 | DBMET00330 | |
| 0.106 | 0.053 | 0.31 | Creatine kinase inhibitor | 0.31 0.004 DBMET00330 | DBMET00330 | |
| 0.11 | 0.061 | 0.472 | Ferrochelatase inhibitor | 0.472 0.003 DBMET00330 | DBMET00330 | |
| 0.106 | 0.059 | 0.335 | Adenylate kinase inhibitor | 0.335 0.005 DBMET00330 | DBMET00330 | |
| 0.149 | 0.103 | 0.173 | 3C-like protease (Human coronavirus) inhibitor | 0.173 0.071 DBMET00330 | DBMET00330 | |
| 0.093 | 0.053 | 0.275 | NADH dehydrogenase inhibitor | 0.275 0.007 DBMET00330 | DBMET00330 | |
| 0.093 | 0.056 | 0.396 | Triose-phosphate isomerase inhibitor | 0.396 0.003 DBMET00330 | DBMET00330 | |
| 0.131 | 0.097 | 0.159 | Pregnane X receptor agonist | 0.159 0.038 DBMET00330 | DBMET00330 | |
| 0.056 | 0.022 | 0.141 | Glucose-6-phosphate isomerase inhibitor | 0.141 0.003 DBMET00330 | DBMET00330 | |
| 0.068 | 0.036 | 0.283 | Carbamoyl phosphate synthetase inhibitor | 0.283 0.005 DBMET00330 | DBMET00330 | |
| 0.045 | 0.013 | 0.05 | Vanilloid 3 antagonist | 0.05 0.009 DBMET00330 | DBMET00330 | |
| 0.079 | 0.048 | 0.088 | Sphingosine 1-phosphate receptor antagonist | 0.088 0.032 DBMET00330 | DBMET00330 | |
| 0.074 | 0.044 | 0.074 | Secretase beta inhibitor | |||
| 0.078 | 0.052 | 0.104 | Na+ K+ transporting ATPase inhibitor | 0.104 0.028 DBMET00330 | DBMET00330 | |
| 0.069 | 0.045 | 0.124 | Exportin-1 inhibitor | 0.124 0.004 DBMET00330 | DBMET00330 | |
| 0.025 | 0.004 | 0.025 | Prokineticin receptor 1 antagonist | |||
| 0.131 | 0.112 | 0.233 | Arachidonic acid antagonist | 0.233 0.01 DBMET00330 | DBMET00330 | |
| 0.055 | 0.039 | 0.069 | Sphingosine 1-phosphate receptor 1 antagonist | 0.069 0.019 DBMET00330 | DBMET00330 | |
| 0.066 | 0.051 | 0.271 | Phosphofructokinase-1 inhibitor | 0.271 0.006 DBMET00330 | DBMET00330 | |
| 0.058 | 0.045 | 0.065 | Potassium channel intermediate-conductance Ca-activated blocker | 0.065 0.032 DBMET00330 | DBMET00330 | |
| 0.052 | 0.041 | 0.199 | Acyl-CoA dehydrogenase inhibitor | 0.199 0.005 DBMET00330 | DBMET00330 | |
| 0.05 | 0.039 | 0.259 | Aconitate hydratase inhibitor | 0.259 0.003 DBMET00330 | DBMET00330 | |
| 0.052 | 0.044 | 0.15 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.15 0.009 DBMET00330 | DBMET00330 | |
| 0.244 | 0.237 | 0.559 | 5 Hydroxytryptamine release inhibitor | 0.559 0.018 DBMET00330 | DBMET00330 | |
| 0.054 | 0.047 | 0.095 | Pregnane X receptor antagonist | 0.095 0.004 DBMET00330 | DBMET00330 | |
| 0.032 | 0.027 | 0.068 | Free fatty acid receptor 1 antagonist | 0.068 0.005 DBMET00330 | DBMET00330 | |
| 0.166 | 0.164 | 0.266 | Nitric-oxide synthase stimulant | 0.266 0.023 DBMET00330 | DBMET00330 | |
| 0.035 | 0.034 | 0.11 | Glutamate (mGluR8) agonist | 0.11 0.003 DBMET00330 | DBMET00330 | |
| 0.044 | 0.049 | 0.053 | Potassium channel (Inward rectifier) activator | 0.053 0.03 DBMET00330 | DBMET00330 | |
| 0.043 | 0.048 | 0.05 | Potassium channel (ATP-sensitive) activator | 0.05 0.029 DBMET00330 | DBMET00330 | |
| 0.16 | 0.166 | 0.44 | 5 Hydroxytryptamine release stimulant | 0.44 0.038 DBMET00330 | DBMET00330 | |
| 0.031 | 0.037 | 0.057 | Calcium-independent phospholipase A2 inhibitor | 0.057 0.003 DBMET00330 | DBMET00330 | |
| 0.027 | 0.033 | 0.053 | Peroxisome proliferator-activated receptor delta agonist | 0.053 0.012 DBMET00330 | DBMET00330 | |
| 0.078 | 0.085 | 0.359 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.359 0.004 DBMET00330 | DBMET00330 | |
| 0.09 | 0.098 | 0.211 | DOPA decarboxylase inhibitor | 0.211 0.005 DBMET00330 | DBMET00330 | |
| 0.088 | 0.099 | 0.255 | GABA C receptor antagonist | 0.255 0.006 DBMET00330 | DBMET00330 | |
| 0.036 | 0.048 | 0.077 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.077 0.004 DBMET00330 | DBMET00330 | |
| 0.016 | 0.029 | 0.158 | Glutamate (mGluR1a) agonist | 0.158 0.003 DBMET00330 | DBMET00330 | |
| 0.013 | 0.025 | 0.024 | Telomerase stimulant | 0.024 0.005 DBMET00330 | DBMET00330 | |
| 0.046 | 0.06 | 0.257 | Biliverdin reductase inhibitor | 0.257 0.004 DBMET00330 | DBMET00330 | |
| 0.007 | 0.024 | 0.025 | Lysophosphatidic acid receptor 3 agonist | 0.025 0.004 DBMET00330 | DBMET00330 | |
| 0.01 | 0.028 | 0.038 | Carbonic anhydrase VIII inhibitor | 0.038 0.003 DBMET00330 | DBMET00330 | |
| 0.01 | 0.028 | 0.038 | Carbonic anhydrase X inhibitor | 0.038 0.003 DBMET00330 | DBMET00330 | |
| 0.058 | 0.079 | 0.266 | Glutamate dehydrogenase inhibitor | 0.266 0.006 DBMET00330 | DBMET00330 | |
| 0.023 | 0.044 | 0.16 | Fumarate hydratase inhibitor | 0.16 0.004 DBMET00330 | DBMET00330 | |
| 0.022 | 0.044 | 0.034 | Purinergic P2Y15 antagonist | 0.034 0.012 DBMET00330 | DBMET00330 | |
| 0.063 | 0.085 | 0.072 | Potassium channel (Tandem pore domain) blocker | 0.072 0.057 DBMET00330 | DBMET00330 | |
| 0.011 | 0.033 | 0.017 | Purinergic P2Y1 agonist | 0.017 0.009 DBMET00330 | DBMET00330 | |
| 0.017 | 0.039 | 0.025 | Fructose-1,6-bisphosphatase 1 inhibitor | 0.025 0.013 DBMET00330 | DBMET00330 | |
| 0.033 | 0.055 | 0.298 | Liver X receptor agonist | 0.298 0.003 DBMET00330 | DBMET00330 | |
| 0.014 | 0.037 | 0.024 | Methylmalonyl-CoA mutase inhibitor | 0.024 0.004 DBMET00330 | DBMET00330 | |
| 0.057 | 0.081 | 0.143 | Glutamate (mGluR6) antagonist | 0.143 0.004 DBMET00330 | DBMET00330 | |
| 0.02 | 0.047 | 0.034 | Glutamate (mGluR2) antagonist | 0.034 0.016 DBMET00330 | DBMET00330 | |
| 0.077 | 0.105 | 0.147 | Anabolic | 0.147 0.019 DBMET00330 | DBMET00330 | |
| 0.038 | 0.066 | 0.59 | Alcohol oxidase inhibitor | 0.59 0.003 DBMET00330 | DBMET00330 | |
| 0.005 | 0.035 | 0.036 | Glutamate (mGluR6) agonist | 0.036 0.003 DBMET00330 | DBMET00330 | |
| 0.026 | 0.055 | 0.057 | Glutamate (mGluR group II) antagonist | 0.057 0.012 DBMET00330 | DBMET00330 | |
| 0.044 | 0.073 | 0.093 | Dihydroorotate oxidase inhibitor | 0.093 0.006 DBMET00330 | DBMET00330 | |
| 0.018 | 0.048 | 0.033 | Vanilloid 2 agonist | 0.033 0.007 DBMET00330 | DBMET00330 | |
| 0.005 | 0.035 | 0.044 | Prostaglandin EP4 agonist | 0.044 0.005 DBMET00330 | DBMET00330 | |
| 0.017 | 0.049 | 0.042 | Lysophosphatidic acid receptor 1 agonist | 0.042 0.005 DBMET00330 | DBMET00330 | |
| 0.076 | 0.109 | 0.258 | Electrolyte absorption antagonist | 0.258 0.005 DBMET00330 | DBMET00330 | |
| 0.052 | 0.086 | 0.245 | Glutamate decarboxylase inhibitor | 0.245 0.004 DBMET00330 | DBMET00330 | |
| 0.011 | 0.047 | 0.043 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.043 0.011 DBMET00330 | DBMET00330 | |
| 0.111 | 0.147 | 0.211 | GABA C receptor rho-2 antagonist | 0.211 0.023 DBMET00330 | DBMET00330 | |
| 0.036 | 0.074 | 0.22 | Argininosuccinate synthase inhibitor | 0.22 0.007 DBMET00330 | DBMET00330 | |
| 0.102 | 0.141 | 0.146 | Vanilloid 1 agonist | 0.146 0.042 DBMET00330 | DBMET00330 | |
| 0.017 | 0.058 | 0.025 | Sodium/glucose cotransporter inhibitor | 0.025 0.018 DBMET00330 | DBMET00330 | |
| 0.025 | 0.066 | 0.054 | Dopamine D5 agonist | 0.054 0.015 DBMET00330 | DBMET00330 | |
| 0.033 | 0.075 | 0.095 | Lysophosphatidic acid 3 receptor antagonist | 0.095 0.005 DBMET00330 | DBMET00330 | |
| 0.015 | 0.058 | 0.024 | Sodium/glucose cotransporter 2 inhibitor | 0.024 0.023 DBMET00330 | DBMET00330 | |
| 0.069 | 0.114 | 0.115 | Estrogen-related receptor beta agonist | 0.115 0.012 DBMET00330 | DBMET00330 | |
| 0.014 | 0.06 | 0.038 | Retinoid X beta receptor antagonist | 0.038 0.003 DBMET00330 | DBMET00330 | |
| 0.013 | 0.059 | 0.027 | Potassium channel (Inward rectifier) 11 blocker | 0.027 0.004 DBMET00330 | DBMET00330 | |
| 0.028 | 0.075 | 0.151 | Ornithine carbamoyltransferase inhibitor | 0.151 0.009 DBMET00330 | DBMET00330 | |
| 0.015 | 0.062 | 0.044 | Nicotinic acid receptor 2 antagonist | 0.044 0.004 DBMET00330 | DBMET00330 | |
| 0.049 | 0.096 | 0.167 | Aminopeptidase I inhibitor | 0.167 0.01 DBMET00330 | DBMET00330 | |
| 0.01 | 0.057 | 0.017 | Complement factor D inhibitor | 0.017 0.015 DBMET00330 | DBMET00330 | |
| 0.013 | 0.061 | 0.046 | Prostaglandin F2 alpha agonist | 0.046 0.005 DBMET00330 | DBMET00330 | |
| 0.012 | 0.061 | 0.032 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | 0.032 0.016 DBMET00330 | DBMET00330 | |
| 0.068 | 0.117 | 0.121 | Granulocyte macrophage colony stimulating factor agonist | 0.121 0.015 DBMET00330 | DBMET00330 | |
| 0.006 | 0.055 | 0.014 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.014 0.007 DBMET00330 | DBMET00330 | |
| 0.028 | 0.077 | 0.048 | Fructose-1,6-bisphosphatase inhibitor | 0.048 0.027 DBMET00330 | DBMET00330 | |
| 0.072 | 0.121 | 0.201 | GABA C receptor rho-1 antagonist | 0.201 0.008 DBMET00330 | DBMET00330 | |
| 0.017 | 0.067 | 0.044 | Cholesterol ester transfer protein antagonist | 0.044 0.01 DBMET00330 | DBMET00330 | |
| 0.005 | 0.056 | 0.016 | Carbonic anhydrase XI inhibitor | 0.016 0.005 DBMET00330 | DBMET00330 | |
| 0.091 | 0.142 | 0.488 | Peroxidase inhibitor | 0.488 0.011 DBMET00330 | DBMET00330 | |
| 0.047 | 0.1 | 0.071 | Potassium channel (ATP-sensitive) blocker | 0.071 0.04 DBMET00330 | DBMET00330 | |
| 0.037 | 0.09 | 0.097 | Androgen agonist | 0.097 0.016 DBMET00330 | DBMET00330 | |
| 0.03 | 0.082 | 0.086 | Kainate receptor agonist | 0.086 0.003 DBMET00330 | DBMET00330 | |
| 0.037 | 0.091 | 0.067 | Heparanase inhibitor | 0.067 0.014 DBMET00330 | DBMET00330 | |
| 0.049 | 0.104 | 0.12 | Glutamate (mGluR7) antagonist | 0.12 0.005 DBMET00330 | DBMET00330 | |
| 0.041 | 0.097 | 0.133 | Purinergic P2X1 antagonist | 0.133 0.009 DBMET00330 | DBMET00330 | |
| 0.019 | 0.077 | 0.032 | Estrogen-related receptor gamma antagonist | 0.032 0.013 DBMET00330 | DBMET00330 | |
| 0.114 | 0.173 | 0.173 | I kappa B kinase epsilon inhibitor | 0.173 0.096 DBMET00330 | DBMET00330 | |
| 0.033 | 0.095 | 0.091 | Alpha-mannosidase inhibitor | 0.091 0.008 DBMET00330 | DBMET00330 | |
| 0.021 | 0.082 | 0.075 | Peroxisome proliferator-activated receptor alpha agonist | 0.075 0.02 DBMET00330 | DBMET00330 | |
| 0.012 | 0.074 | 0.025 | Neuraminidase (Influenza B) inhibitor | 0.025 0.007 DBMET00330 | DBMET00330 | |
| 0.003 | 0.066 | 0.009 | Thyroid hormone beta agonist | 0.009 0.006 DBMET00330 | DBMET00330 | |
| 0.042 | 0.105 | 0.403 | Porphobilinogen synthase inhibitor | 0.403 0.004 DBMET00330 | DBMET00330 | |
| 0.074 | 0.138 | 0.15 | Glutamate (mGluR7) agonist | 0.15 0.012 DBMET00330 | DBMET00330 | |
| 0.009 | 0.073 | 0.018 | Vitamin D receptor agonist | 0.018 0.009 DBMET00330 | DBMET00330 | |
| 0.015 | 0.08 | 0.113 | Glutamate (mGluR1) agonist | 0.113 0.003 DBMET00330 | DBMET00330 | |
| 0.049 | 0.114 | 0.063 | Transcription factor RelA inhibitor | 0.063 0.046 DBMET00330 | DBMET00330 | |
| 0.007 | 0.074 | 0.03 | Prostaglandin E2 agonist | 0.03 0.011 DBMET00330 | DBMET00330 | |
| 0.051 | 0.12 | 0.08 | Myeloperoxidase inhibitor | 0.08 0.067 DBMET00330 | DBMET00330 | |
| 0.007 | 0.075 | 0.027 | Thromboxane A2 agonist | 0.027 0.004 DBMET00330 | DBMET00330 | |
| 0.005 | 0.074 | 0.019 | Aminopeptidase A inhibitor | 0.019 0.011 DBMET00330 | DBMET00330 | |
| 0.021 | 0.09 | 0.057 | Glutamate (mGluR3) agonist | 0.057 0.004 DBMET00330 | DBMET00330 | |
| 0.022 | 0.09 | 0.076 | Membrane dipeptidase inhibitor | 0.076 0.006 DBMET00330 | DBMET00330 | |
| 0.019 | 0.088 | 0.079 | Toll-Like receptor 2 agonist | 0.079 0.017 DBMET00330 | DBMET00330 | |
| 0.027 | 0.097 | 0.075 | Adenylate cyclase 1 inhibitor | 0.075 0.01 DBMET00330 | DBMET00330 | |
| 0.012 | 0.083 | 0.043 | Prostaglandin agonist | 0.043 0.012 DBMET00330 | DBMET00330 | |
| 0.019 | 0.09 | 0.026 | Glucosylceramidase stimulant | 0.026 0.023 DBMET00330 | DBMET00330 | |
| 0.019 | 0.09 | 0.029 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.029 0.013 DBMET00330 | DBMET00330 | |
| 0.069 | 0.142 | 0.153 | Glutamate release inhibitor | 0.153 0.009 DBMET00330 | DBMET00330 | |
| 0.021 | 0.093 | 0.059 | Retinoid X alpha receptor antagonist | 0.059 0.004 DBMET00330 | DBMET00330 | |
| 0.025 | 0.098 | 0.061 | Nerve growth factor antagonist | 0.061 0.009 DBMET00330 | DBMET00330 | |
| 0.014 | 0.087 | 0.037 | Thyroid hormone agonist | 0.037 0.007 DBMET00330 | DBMET00330 | |
| 0.009 | 0.083 | 0.047 | Uridine phosphorylase inhibitor | 0.047 0.009 DBMET00330 | DBMET00330 | |
| 0.015 | 0.089 | 0.04 | Calcitonin receptor agonist | 0.04 0.02 DBMET00330 | DBMET00330 | |
| 0.051 | 0.126 | 0.082 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.082 0.033 DBMET00330 | DBMET00330 | |
| 0.016 | 0.091 | 0.037 | Epoxide hydrolase 1 inhibitor | 0.037 0.013 DBMET00330 | DBMET00330 | |
| 0.012 | 0.088 | 0.025 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.025 0.008 DBMET00330 | DBMET00330 | |
| 0.01 | 0.087 | 0.02 | Antibiotic Anthracycline-like | 0.02 0.011 DBMET00330 | DBMET00330 | |
| 0.049 | 0.127 | 0.149 | Glycine receptor agonist | 0.149 0.007 DBMET00330 | DBMET00330 | |
| 0.022 | 0.101 | 0.068 | Retinoid X receptor antagonist | 0.068 0.004 DBMET00330 | DBMET00330 | |
| 0.01 | 0.089 | 0.022 | Protease (Human cytomegalovirus) inhibitor | 0.022 0.015 DBMET00330 | DBMET00330 | |
| 0.01 | 0.091 | 0.028 | Lysophosphatidic acid 1 receptor antagonist | 0.028 0.007 DBMET00330 | DBMET00330 | |
| 0.018 | 0.099 | 0.029 | Hedgehog signaling activator | 0.029 0.016 DBMET00330 | DBMET00330 | |
| 0.063 | 0.146 | 0.115 | D-Ala-D-Ala ligase inhibitor | 0.115 0.016 DBMET00330 | DBMET00330 | |
| 0.054 | 0.137 | 0.096 | Vanilloid 4 agonist | 0.096 0.02 DBMET00330 | DBMET00330 | |
| 0.022 | 0.104 | 0.08 | Mannosidase inhibitor | 0.08 0.009 DBMET00330 | DBMET00330 | |
| 0.019 | 0.104 | 0.067 | Guanylate cyclase inhibitor | 0.067 0.006 DBMET00330 | DBMET00330 | |
| 0.017 | 0.103 | 0.042 | Oxytocin agonist | 0.042 0.029 DBMET00330 | DBMET00330 | |
| 0.099 | 0.184 | 0.193 | Adenylate cyclase stimulant | 0.193 0.017 DBMET00330 | DBMET00330 | |
| 0.022 | 0.108 | 0.074 | Tryptophan 5 hydroxylase inhibitor | 0.074 0.003 DBMET00330 | DBMET00330 | |
| 0.011 | 0.097 | 0.031 | Prostaglandin EP4 antagonist | 0.031 0.015 DBMET00330 | DBMET00330 | |
| 0.05 | 0.137 | 0.212 | Aminopeptidase B inhibitor | 0.212 0.019 DBMET00330 | DBMET00330 | |
| 0.01 | 0.098 | 0.046 | Lysine carboxypeptidase inhibitor | 0.046 0.009 DBMET00330 | DBMET00330 | |
| 0.014 | 0.102 | 0.052 | Liver X receptor beta agonist | 0.052 0.01 DBMET00330 | DBMET00330 | |
| 0.062 | 0.152 | 0.289 | ABCA1 expression enhancer | 0.289 0.005 DBMET00330 | DBMET00330 | |
| 0.065 | 0.156 | 0.219 | Amylase inhibitor | 0.219 0.038 DBMET00330 | DBMET00330 | |
| 0.031 | 0.122 | 0.048 | Squalene epoxidase inhibitor | 0.048 0.037 DBMET00330 | DBMET00330 | |
| 0.06 | 0.152 | 0.267 | Cystathionine beta-synthase inhibitor | 0.267 0.013 DBMET00330 | DBMET00330 | |
| 0.049 | 0.142 | 0.07 | Calcium channel P-type blocker | 0.07 0.029 DBMET00330 | DBMET00330 | |
| 0.003 | 0.096 | 0.016 | Thromboxane agonist | 0.016 0.004 DBMET00330 | DBMET00330 | |
| 0.029 | 0.123 | 0.06 | Dopamine beta hydroxylase inhibitor | 0.06 0.015 DBMET00330 | DBMET00330 | |
| 0.013 | 0.11 | 0.045 | Farnesoid X receptor agonist | 0.045 0.019 DBMET00330 | DBMET00330 | |
| 0.1 | 0.197 | 0.233 | Interferon gamma antagonist | 0.233 0.032 DBMET00330 | DBMET00330 | |
| 0.02 | 0.119 | 0.067 | Liver X receptor alpha agonist | 0.067 0.009 DBMET00330 | DBMET00330 | |
| 0.013 | 0.112 | 0.106 | Retinoid X alpha receptor agonist | 0.106 0.005 DBMET00330 | DBMET00330 | |
| 0.007 | 0.106 | 0.02 | Thyroid hormone alpha agonist | 0.02 0.006 DBMET00330 | DBMET00330 | |
| 0.006 | 0.107 | 0.074 | Arginase inhibitor | 0.074 0.007 DBMET00330 | DBMET00330 | |
| 0.032 | 0.133 | 0.248 | Catalase inhibitor | 0.248 0.009 DBMET00330 | DBMET00330 | |
| 0.024 | 0.127 | 0.058 | Potassium channel (Inward rectifier) blocker | 0.058 0.026 DBMET00330 | DBMET00330 | |
| 0.023 | 0.125 | 0.081 | AICAR transformylase inhibitor | 0.081 0.007 DBMET00330 | DBMET00330 | |
| 0.032 | 0.135 | 0.231 | Phenylalanine 4-hydroxylase inhibitor | 0.231 0.005 DBMET00330 | DBMET00330 | |
| 0.009 | 0.116 | 0.024 | Isoleucine-tRNA ligase inhibitor | 0.024 0.013 DBMET00330 | DBMET00330 | |
| 0.042 | 0.149 | 0.168 | GABA aminotransferase inhibitor | 0.168 0.005 DBMET00330 | DBMET00330 | |
| 0.009 | 0.118 | 0.095 | Retinoid X receptor agonist | 0.095 0.005 DBMET00330 | DBMET00330 | |
| 0.023 | 0.132 | 0.053 | Thymidine kinase inhibitor | 0.053 0.017 DBMET00330 | DBMET00330 | |
| 0.05 | 0.161 | 0.093 | MDM2 inhibitor | 0.093 0.01 DBMET00330 | DBMET00330 | |
| 0.014 | 0.131 | 0.025 | Thymidine phosphorylase inhibitor | 0.025 0.021 DBMET00330 | DBMET00330 | |
| 0.084 | 0.2 | 0.231 | Mannose-6-phosphate isomerase inhibitor | 0.231 0.017 DBMET00330 | DBMET00330 | |
| 0.003 | 0.12 | 0.03 | G-protein-coupled receptor 120 agonist | 0.03 0.005 DBMET00330 | DBMET00330 | |
| 0.005 | 0.123 | 0.019 | Nicotinic acid receptor 1 antagonist | 0.019 0.01 DBMET00330 | DBMET00330 | |
| 0.026 | 0.145 | 0.065 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.065 0.025 DBMET00330 | DBMET00330 | |
| 0.009 | 0.13 | 0.064 | Liver X receptor beta antagonist | 0.064 0.005 DBMET00330 | DBMET00330 | |
| 0.03 | 0.151 | 0.272 | Histidine decarboxylase inhibitor | 0.272 0.008 DBMET00330 | DBMET00330 | |
| 0.016 | 0.138 | 0.062 | GABA uptake inhibitor | 0.062 0.009 DBMET00330 | DBMET00330 | |
| 0.012 | 0.135 | 0.032 | Carnitine palmitoyltransferase 1 inhibitor | 0.032 0.027 DBMET00330 | DBMET00330 | |
| 0.12 | 0.246 | 0.35 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.35 0.013 DBMET00330 | DBMET00330 | |
| 0.01 | 0.139 | 0.032 | Carnitine palmitoyltransferase inhibitor | 0.032 0.027 DBMET00330 | DBMET00330 | |
| 0.01 | 0.139 | 0.041 | Phosphoglycerate kinase inhibitor | 0.041 0.019 DBMET00330 | DBMET00330 | |
| 0.035 | 0.165 | 0.069 | Protease 3C (Human rhinovirus) inhibitor | 0.069 0.038 DBMET00330 | DBMET00330 | |
| 0.009 | 0.14 | 0.031 | Estradiol 17 beta-dehydrogenase 3 inhibitor | 0.031 0.024 DBMET00330 | DBMET00330 | |
| 0.127 | 0.265 | 0.275 | RNA-directed DNA polymerase inhibitor | 0.275 0.038 DBMET00330 | DBMET00330 | |
| 0.048 | 0.186 | 0.074 | Estrogen receptor alpha antagonist | 0.074 0.059 DBMET00330 | DBMET00330 | |
| 0.039 | 0.178 | 0.114 | Glycine receptor antagonist | 0.114 0.021 DBMET00330 | DBMET00330 | |
| 0.007 | 0.145 | 0.042 | Progesterone antagonist | 0.042 0.021 DBMET00330 | DBMET00330 | |
| 0.065 | 0.204 | 0.207 | Toll-Like receptor 2 antagonist | 0.207 0.02 DBMET00330 | DBMET00330 | |
| 0.029 | 0.17 | 0.041 | Heme oxygenase inhibitor | 0.041 0.037 DBMET00330 | DBMET00330 | |
| 0.058 | 0.2 | 0.123 | Carbonic anhydrase XV inhibitor | 0.123 0.044 DBMET00330 | DBMET00330 | |
| 0.099 | 0.243 | 0.255 | Neurotrophic factor enhancer | 0.255 0.036 DBMET00330 | DBMET00330 | |
| 0.031 | 0.176 | 0.1 | Phospholipase D inhibitor | 0.1 0.014 DBMET00330 | DBMET00330 | |
| 0.016 | 0.161 | 0.062 | Adenosine deaminase inhibitor | 0.062 0.019 DBMET00330 | DBMET00330 | |
| 0.065 | 0.21 | 0.158 | Cathepsin H inhibitor | 0.158 0.041 DBMET00330 | DBMET00330 | |
| 0.03 | 0.176 | 0.083 | CD45 antagonist | 0.083 0.011 DBMET00330 | DBMET00330 | |
| 0.042 | 0.189 | 0.145 | Keratolytic | 0.145 0.015 DBMET00330 | DBMET00330 | |
| 0.012 | 0.159 | 0.044 | ATP citrate lysase inhibitor | 0.044 0.01 DBMET00330 | DBMET00330 | |
| 0.015 | 0.163 | 0.037 | Ceramide glucosyltransferase inhibitor | 0.037 0.021 DBMET00330 | DBMET00330 | |
| 0.112 | 0.264 | 0.417 | Superoxide dismutase inhibitor | 0.417 0.024 DBMET00330 | DBMET00330 | |
| 0.014 | 0.167 | 0.11 | Glutamate (mGluR3) antagonist | 0.11 0.004 DBMET00330 | DBMET00330 | |
| 0.062 | 0.215 | 0.175 | Photosensitizer | 0.175 0.019 DBMET00330 | DBMET00330 | |
| 0.011 | 0.165 | 0.047 | Lysophosphatidic acid 2 receptor antagonist | 0.047 0.009 DBMET00330 | DBMET00330 | |
| 0.002 | 0.157 | 0.008 | Integrin alpha5beta6 antagonist | 0.008 0.004 DBMET00330 | DBMET00330 | |
| 0.057 | 0.214 | 0.162 | Microtubule formation inhibitor | 0.162 0.032 DBMET00330 | DBMET00330 | |
| 0.008 | 0.167 | 0.019 | CXC chemokine 5 receptor antagonist | 0.019 0.01 DBMET00330 | DBMET00330 | |
| 0.043 | 0.202 | 0.14 | Prolactin inhibitor | 0.14 0.026 DBMET00330 | DBMET00330 | |
| 0.011 | 0.171 | 0.044 | Dihydropteroate synthase inhibitor | 0.044 0.022 DBMET00330 | DBMET00330 | |
| 0.084 | 0.244 | 0.581 | Aldehyde oxidase inhibitor | 0.581 0.022 DBMET00330 | DBMET00330 | |
| 0.023 | 0.185 | 0.046 | Leukotriene C4 antagonist | 0.046 0.014 DBMET00330 | DBMET00330 | |
| 0.045 | 0.208 | 0.194 | Cholesterol synthesis inhibitor | 0.194 0.028 DBMET00330 | DBMET00330 | |
| 0.087 | 0.252 | 0.333 | Non-steroidal antiinflammatory agent | 0.333 0.022 DBMET00330 | DBMET00330 | |
| 0.011 | 0.177 | 0.037 | Integrin alpha2beta1 antagonist | 0.037 0.007 DBMET00330 | DBMET00330 | |
| 0.036 | 0.202 | 0.068 | Leukotriene C antagonist | 0.068 0.016 DBMET00330 | DBMET00330 | |
| 0.046 | 0.212 | 0.128 | GABA B receptor agonist | 0.128 0.005 DBMET00330 | DBMET00330 | |
| 0.05 | 0.219 | 0.085 | mTOR complex 2 inhibitor | 0.085 0.057 DBMET00330 | DBMET00330 | |
| 0.017 | 0.186 | 0.057 | Dihydroorotase inhibitor | 0.057 0.018 DBMET00330 | DBMET00330 | |
| 0.015 | 0.185 | 0.045 | Dihydroorotate dehydrogenase inhibitor | 0.045 0.044 DBMET00330 | DBMET00330 | |
| 0.042 | 0.212 | 0.212 | HIV-1 integrase (Overall Integration) inhibitor | 0.212 0.009 DBMET00330 | DBMET00330 | |
| 0.036 | 0.207 | 0.065 | Ryanodine receptor antagonist | 0.065 0.026 DBMET00330 | DBMET00330 | |
| 0.01 | 0.181 | 0.054 | Geranyltranstransferase inhibitor | 0.054 0.019 DBMET00330 | DBMET00330 | |
| 0.004 | 0.178 | 0.038 | Prostaglandin EP2 agonist | 0.038 0.009 DBMET00330 | DBMET00330 | |
| 0.024 | 0.198 | 0.052 | Sphingosine kinase 2 inhibitor | 0.052 0.044 DBMET00330 | DBMET00330 | |
| 0.006 | 0.181 | 0.059 | Carbonic anhydrase IV inhibitor | 0.059 0.02 DBMET00330 | DBMET00330 | |
| 0.022 | 0.197 | 0.054 | Aldosterone antagonist | 0.054 0.025 DBMET00330 | DBMET00330 | |
| 0.034 | 0.209 | 0.124 | Ornithine decarboxylase inhibitor | 0.124 0.023 DBMET00330 | DBMET00330 | |
| 0.051 | 0.23 | 0.105 | Sodium channel (voltage-gated) blocker | 0.105 0.103 DBMET00330 | DBMET00330 | |
| 0.014 | 0.194 | 0.037 | Carboxypeptidase B inhibitor | 0.037 0.017 DBMET00330 | DBMET00330 | |
| 0.009 | 0.191 | 0.06 | Sphingosine 1-phosphate receptor 1 agonist | 0.06 0.013 DBMET00330 | DBMET00330 | |
| 0.003 | 0.185 | 0.016 | Egl nine homolog 3 inhibitor | 0.016 0.005 DBMET00330 | DBMET00330 | |
| 0.036 | 0.22 | 0.053 | Immunoglobulin Fc receptor antagonist | 0.053 0.046 DBMET00330 | DBMET00330 | |
| 0.019 | 0.204 | 0.054 | Cholesterol esterase inhibitor | 0.054 0.025 DBMET00330 | DBMET00330 | |
| 0.024 | 0.21 | 0.039 | CF transmembrane conductance regulator antagonist | 0.039 0.031 DBMET00330 | DBMET00330 | |
| 0.01 | 0.197 | 0.077 | Carbonic anhydrase VB inhibitor | 0.077 0.024 DBMET00330 | DBMET00330 | |
| 0.022 | 0.211 | 0.088 | Carbonic anhydrase stimulant | 0.088 0.022 DBMET00330 | DBMET00330 | |
| 0.008 | 0.197 | 0.065 | Antimetabolite | 0.065 0.023 DBMET00330 | DBMET00330 | |
| 0.026 | 0.217 | 0.05 | Bombesin 2 receptor antagonist | 0.05 0.033 DBMET00330 | DBMET00330 | |
| 0.036 | 0.228 | 0.131 | Carbonic anhydrase VI inhibitor | 0.131 0.026 DBMET00330 | DBMET00330 | |
| 0.078 | 0.271 | 0.167 | Melanin inhibitor | 0.167 0.062 DBMET00330 | DBMET00330 | |
| 0.026 | 0.219 | 0.105 | Androgen antagonist | 0.105 0.043 DBMET00330 | DBMET00330 | |
| 0.056 | 0.25 | 0.078 | CC chemokine 5 receptor agonist | 0.078 0.073 DBMET00330 | DBMET00330 | |
| 0.016 | 0.212 | 0.033 | Protein kinase (CK2) beta inhibitor | 0.033 0.023 DBMET00330 | DBMET00330 | |
| 0.002 | 0.2 | 0.029 | Peroxisome proliferator-activated receptor alpha antagonist | 0.029 0.012 DBMET00330 | DBMET00330 | |
| 0.015 | 0.213 | 0.119 | NMDA receptor glycine site agonist | 0.119 0.009 DBMET00330 | DBMET00330 | |
| 0.031 | 0.229 | 0.076 | Interferon inducer | 0.076 0.028 DBMET00330 | DBMET00330 | |
| 0.045 | 0.245 | 0.082 | MAP kinase kinase 7 inhibitor | 0.082 0.041 DBMET00330 | DBMET00330 | |
| 0.02 | 0.222 | 0.065 | HCV NS3/NS4A protease inhibitor | 0.065 0.017 DBMET00330 | DBMET00330 | |
| 0.046 | 0.248 | 0.178 | Mucolytic | 0.178 0.02 DBMET00330 | DBMET00330 | |
| 0.024 | 0.227 | 0.061 | Topoisomerase II beta inhibitor | 0.061 0.021 DBMET00330 | DBMET00330 | |
| 0.014 | 0.217 | 0.051 | Integrin alpha2 antagonist | 0.051 0.011 DBMET00330 | DBMET00330 | |
| 0.036 | 0.24 | 0.097 | Sphingomyelinase inhibitor | 0.097 0.064 DBMET00330 | DBMET00330 | |
| 0.025 | 0.23 | 0.103 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.103 0.036 DBMET00330 | DBMET00330 | |
| 0.021 | 0.226 | 0.093 | Glutamate (mGluR4) antagonist | 0.093 0.006 DBMET00330 | DBMET00330 | |
| 0.005 | 0.21 | 0.049 | Kynurenine 3 monooxygenase inhibitor | 0.049 0.007 DBMET00330 | DBMET00330 | |
| 0.003 | 0.209 | 0.034 | Prostaglandin H2 antagonist | 0.034 0.009 DBMET00330 | DBMET00330 | |
| 0.017 | 0.223 | 0.093 | Diacylglycerol O-acyltransferase inhibitor | 0.093 0.009 DBMET00330 | DBMET00330 | |
| 0.089 | 0.297 | 0.236 | Phospholipase C inhibitor | 0.236 0.028 DBMET00330 | DBMET00330 | |
| 0.006 | 0.215 | 0.048 | Glucagon receptor antagonist | 0.048 0.011 DBMET00330 | DBMET00330 | |
| 0.025 | 0.235 | 0.067 | Epoxide hydrolase inhibitor | 0.067 0.058 DBMET00330 | DBMET00330 | |
| 0.043 | 0.255 | 0.144 | Nav1.6 sodium channel blocker | 0.144 0.062 DBMET00330 | DBMET00330 | |
| 0.006 | 0.219 | 0.018 | 5-Alpha-reductase 2 inhibitor | 0.018 0.015 DBMET00330 | DBMET00330 | |
| 0.006 | 0.22 | 0.051 | 5-Alpha-reductase inhibitor | 0.051 0.018 DBMET00330 | DBMET00330 | |
| 0.008 | 0.223 | 0.021 | Caspase 8 inhibitor | 0.021 0.011 DBMET00330 | DBMET00330 | |
| 0.02 | 0.237 | 0.091 | Carbonic anhydrase VA inhibitor | 0.091 0.029 DBMET00330 | DBMET00330 | |
| 0.057 | 0.276 | 0.221 | Protein kinase stimulant | 0.221 0.035 DBMET00330 | DBMET00330 | |
| 0.022 | 0.242 | 0.053 | Epithelial sodium channel blocker | 0.053 0.042 DBMET00330 | DBMET00330 | |
| 0.015 | 0.236 | 0.073 | Prostaglandin-E synthase inhibitor | 0.073 0.045 DBMET00330 | DBMET00330 | |
| 0.007 | 0.229 | 0.058 | Ribonucleotide reductase inhibitor | 0.058 0.038 DBMET00330 | DBMET00330 | |
| 0.064 | 0.286 | 0.141 | Thiol protease inhibitor | 0.141 0.078 DBMET00330 | DBMET00330 | |
| 0.017 | 0.24 | 0.091 | Carbonic anhydrase V inhibitor | 0.091 0.03 DBMET00330 | DBMET00330 | |
| 0.043 | 0.267 | 0.139 | Carbonic anhydrase III inhibitor | 0.139 0.033 DBMET00330 | DBMET00330 | |
| 0.007 | 0.232 | 0.056 | Ribonucleoside-diphosphate reductase inhibitor | 0.056 0.037 DBMET00330 | DBMET00330 | |
| 0.005 | 0.231 | 0.039 | G protein-coupled receptor agonist | 0.039 0.025 DBMET00330 | DBMET00330 | |
| 0.002 | 0.231 | 0.012 | Angiotensin AT1B receptor antagonist | 0.012 0.011 DBMET00330 | DBMET00330 | |
| 0.003 | 0.233 | 0.014 | Integrin alphaVbeta6 antagonist | 0.014 0.011 DBMET00330 | DBMET00330 | |
| 0.009 | 0.238 | 0.047 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | 0.047 0.011 DBMET00330 | DBMET00330 | |
| 0.044 | 0.275 | 0.123 | Lanosterol 14 alpha demethylase inhibitor | 0.123 0.028 DBMET00330 | DBMET00330 | |
| 0.023 | 0.257 | 0.133 | NMDA receptor agonist | 0.133 0.01 DBMET00330 | DBMET00330 | |
| 0.159 | 0.395 | 0.474 | Caspase 9 stimulant | 0.474 0.071 DBMET00330 | DBMET00330 | |
| 0.014 | 0.251 | 0.043 | MAP3K5 inhibitor | 0.043 0.021 DBMET00330 | DBMET00330 | |
| 0.012 | 0.249 | 0.063 | Sphingosine 1-phosphate receptor agonist | 0.063 0.014 DBMET00330 | DBMET00330 | |
| 0.037 | 0.276 | 0.116 | Glutathione S-transferase inhibitor | 0.116 0.025 DBMET00330 | DBMET00330 | |
| 0.005 | 0.245 | 0.074 | Urate transporter 1 inhibitor | 0.074 0.009 DBMET00330 | DBMET00330 | |
| 0.002 | 0.243 | 0.013 | Integrin beta2 antagonist | 0.013 0.008 DBMET00330 | DBMET00330 | |
| 0.02 | 0.26 | 0.102 | Monophenol monooxygenase inhibitor | 0.102 0.075 DBMET00330 | DBMET00330 | |
| 0.004 | 0.249 | 0.024 | NMDA receptor glycine site antagonist | 0.024 0.017 DBMET00330 | DBMET00330 | |
| 0.013 | 0.259 | 0.04 | Glutamate (mGluR4) agonist | 0.04 0.015 DBMET00330 | DBMET00330 | |
| 0.027 | 0.273 | 0.092 | Interferon agonist | 0.092 0.036 DBMET00330 | DBMET00330 | |
| 0.023 | 0.27 | 0.107 | Cathepsin G inhibitor | 0.107 0.031 DBMET00330 | DBMET00330 | |
| 0.061 | 0.308 | 0.23 | Hexokinase inhibitor | 0.23 0.022 DBMET00330 | DBMET00330 | |
| 0.01 | 0.257 | 0.056 | Leukocyte elastase inhibitor | 0.056 0.02 DBMET00330 | DBMET00330 | |
| 0.017 | 0.266 | 0.137 | Sphingosine 1-phosphate receptor 4 agonist | 0.137 0.011 DBMET00330 | DBMET00330 | |
| 0.026 | 0.277 | 0.21 | Alcohol dehydrogenase inhibitor | 0.21 0.011 DBMET00330 | DBMET00330 | |
| 0.048 | 0.3 | 0.16 | Cyclooxygenase 3 inhibitor | 0.16 0.04 DBMET00330 | DBMET00330 | |
| 0.02 | 0.275 | 0.084 | Glutamate (mGluR group III) antagonist | 0.084 0.007 DBMET00330 | DBMET00330 | |
| 0.027 | 0.282 | 0.159 | Expectorant | 0.159 0.032 DBMET00330 | DBMET00330 | |
| 0.004 | 0.26 | 0.026 | CXC chemokine 2 receptor antagonist | 0.026 0.019 DBMET00330 | DBMET00330 | |
| 0.102 | 0.359 | 0.164 | Heat shock protein 70 antagonist | 0.164 0.024 DBMET00330 | DBMET00330 | |
| 0.062 | 0.325 | 0.221 | Antiamyloidogenic | 0.221 0.086 DBMET00330 | DBMET00330 | |
| 0.089 | 0.352 | 0.318 | DNA synthesis inhibitor | 0.318 0.038 DBMET00330 | DBMET00330 | |
| 0.007 | 0.271 | 0.027 | Calcium-sensing receptor agonist | 0.027 0.017 DBMET00330 | DBMET00330 | |
| 0.015 | 0.288 | 0.053 | Leukotriene B4 antagonist | 0.053 0.038 DBMET00330 | DBMET00330 | |
| 0.107 | 0.381 | 0.243 | Antibacterial | 0.243 0.184 DBMET00330 | DBMET00330 | |
| 0.09 | 0.365 | 0.469 | Cholesterol antagonist | 0.469 0.038 DBMET00330 | DBMET00330 | |
| 0.02 | 0.295 | 0.087 | Carbonic anhydrase XIII inhibitor | 0.087 0.045 DBMET00330 | DBMET00330 | |
| 0.002 | 0.277 | 0.031 | Kainate receptor 1 antagonist | 0.031 0.01 DBMET00330 | DBMET00330 | |
| 0.009 | 0.285 | 0.068 | Thymidylate synthase inhibitor | 0.068 0.013 DBMET00330 | DBMET00330 | |
| 0.013 | 0.291 | 0.064 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.064 0.036 DBMET00330 | DBMET00330 | |
| 0.029 | 0.309 | 0.086 | Peroxisome proliferator-activated receptor gamma antagonist | 0.086 0.026 DBMET00330 | DBMET00330 | |
| 0.005 | 0.29 | 0.063 | Kainate receptor 2 antagonist | 0.063 0.011 DBMET00330 | DBMET00330 | |
| 0.008 | 0.294 | 0.025 | ICAM 1 antagonist | 0.025 0.011 DBMET00330 | DBMET00330 | |
| 0.015 | 0.302 | 0.089 | Glutamate (mGluR group III) agonist | 0.089 0.011 DBMET00330 | DBMET00330 | |
| 0.015 | 0.303 | 0.051 | GABA B receptor antagonist | 0.051 0.019 DBMET00330 | DBMET00330 | |
| 0.008 | 0.298 | 0.156 | Liver X receptor antagonist | 0.156 0.004 DBMET00330 | DBMET00330 | |
| 0.008 | 0.299 | 0.045 | Glutamate (mGluR group I) agonist | 0.045 0.036 DBMET00330 | DBMET00330 | |
| 0.007 | 0.299 | 0.049 | Angiotensin AT1 receptor antagonist | 0.049 0.019 DBMET00330 | DBMET00330 | |
| 0.044 | 0.336 | 0.205 | Aldehyde dehydrogenase inhibitor | 0.205 0.026 DBMET00330 | DBMET00330 | |
| 0.01 | 0.304 | 0.076 | Thromboxane antagonist | 0.076 0.022 DBMET00330 | DBMET00330 | |
| 0.007 | 0.306 | 0.067 | Thromboxane A2 antagonist | 0.067 0.023 DBMET00330 | DBMET00330 | |
| 0.006 | 0.309 | 0.044 | Phosphorylase inhibitor | 0.044 0.034 DBMET00330 | DBMET00330 | |
| 0.011 | 0.316 | 0.053 | AMPA 4 receptor antagonist | 0.053 0.013 DBMET00330 | DBMET00330 | |
| 0.007 | 0.313 | 0.045 | Nicotinic acid receptor agonist | 0.045 0.017 DBMET00330 | DBMET00330 | |
| 0.009 | 0.316 | 0.046 | Glycine transporter 2 inhibitor | 0.046 0.033 DBMET00330 | DBMET00330 | |
| 0.019 | 0.328 | 0.054 | Botulinum neurotoxin type A inhibitor | 0.054 0.048 DBMET00330 | DBMET00330 | |
| 0.01 | 0.322 | 0.05 | Xanthine dehydrogenase inhibitor | 0.05 0.046 DBMET00330 | DBMET00330 | |
| 0.008 | 0.321 | 0.036 | Angiotensin II receptor antagonist | 0.036 0.019 DBMET00330 | DBMET00330 | |
| 0.002 | 0.315 | 0.016 | Egl nine homolog 1 inhibitor | 0.016 0.009 DBMET00330 | DBMET00330 | |
| 0.006 | 0.325 | 0.03 | LFA antagonist | 0.03 0.015 DBMET00330 | DBMET00330 | |
| 0.03 | 0.357 | 0.09 | Beta glucuronidase inhibitor | 0.09 0.087 DBMET00330 | DBMET00330 | |
| 0.09 | 0.42 | 0.314 | Insulysin inhibitor | 0.314 0.05 DBMET00330 | DBMET00330 | |
| 0.008 | 0.338 | 0.063 | Neutrophil collagenase inhibitor | 0.063 0.047 DBMET00330 | DBMET00330 | |
| 0.032 | 0.365 | 0.111 | Bile acid receptor antagonist | 0.111 0.03 DBMET00330 | DBMET00330 | |
| 0.01 | 0.346 | 0.072 | Leukotriene antagonist | 0.072 0.038 DBMET00330 | DBMET00330 | |
| 0.049 | 0.387 | 0.31 | Interleukin agonist | 0.31 0.043 DBMET00330 | DBMET00330 | |
| 0.004 | 0.343 | 0.067 | Kainate receptor antagonist | 0.067 0.013 DBMET00330 | DBMET00330 | |
| 0.078 | 0.419 | 0.199 | Neurotensin receptor agonist | 0.199 0.035 DBMET00330 | DBMET00330 | |
| 0.041 | 0.383 | 0.117 | TRPA1 agonist | 0.117 0.061 DBMET00330 | DBMET00330 | |
| 0.021 | 0.367 | 0.09 | Macrophage migration inhibitory factor inhibitor | 0.09 0.041 DBMET00330 | DBMET00330 | |
| 0.039 | 0.389 | 0.088 | Phosphodiesterase 6D inhibitor | 0.088 0.082 DBMET00330 | DBMET00330 | |
| 0.028 | 0.381 | 0.116 | MAP kinase kinase 1 inhibitor | 0.116 0.039 DBMET00330 | DBMET00330 | |
| 0.06 | 0.415 | 0.206 | ATPase inhibitor | 0.206 0.032 DBMET00330 | DBMET00330 | |
| 0.015 | 0.37 | 0.05 | Carnitine palmitoyltransferase 1B inhibitor | 0.05 0.029 DBMET00330 | DBMET00330 | |
| 0.002 | 0.36 | 0.024 | Calcium-dependent phospholipase A2 inhibitor | 0.024 0.004 DBMET00330 | DBMET00330 | |
| 0.004 | 0.365 | 0.031 | AMPA 3 receptor antagonist | 0.031 0.02 DBMET00330 | DBMET00330 | |
| 0.011 | 0.379 | 0.058 | Thromboxane synthase inhibitor | 0.058 0.03 DBMET00330 | DBMET00330 | |
| 0.033 | 0.409 | 0.146 | Adenylate cyclase inhibitor | 0.146 0.047 DBMET00330 | DBMET00330 | |
| 0.079 | 0.456 | 0.446 | Histamine release inhibitor | 0.446 0.052 DBMET00330 | DBMET00330 | |
| 0.005 | 0.383 | 0.044 | NMDA receptor subunit 3B antagonist | 0.044 0.03 DBMET00330 | DBMET00330 | |
| 0.052 | 0.431 | 0.134 | DNA repair enzyme inhibitor | 0.134 0.05 DBMET00330 | DBMET00330 | |
| 0.026 | 0.408 | 0.137 | Caspase 3 inhibitor | 0.137 0.039 DBMET00330 | DBMET00330 | |
| 0.005 | 0.393 | 0.049 | Purinergic P2Y antagonist | 0.049 0.027 DBMET00330 | DBMET00330 | |
| 0.034 | 0.429 | 0.243 | Insulin sensitizer | 0.243 0.038 DBMET00330 | DBMET00330 | |
| 0.004 | 0.402 | 0.036 | NMDA receptor subunit 3A antagonist | 0.036 0.028 DBMET00330 | DBMET00330 | |
| 0.006 | 0.408 | 0.048 | RNA-directed RNA polymerase inhibitor | 0.048 0.014 DBMET00330 | DBMET00330 | |
| 0.027 | 0.434 | 0.092 | Xanthine oxidase inhibitor | 0.092 0.069 DBMET00330 | DBMET00330 | |
| 0.006 | 0.413 | 0.056 | NMDA 2C receptor antagonist | 0.056 0.051 DBMET00330 | DBMET00330 | |
| 0.061 | 0.471 | 0.293 | Antithrombotic | 0.293 0.093 DBMET00330 | DBMET00330 | |
| 0.018 | 0.432 | 0.131 | Potassium channel (Ca-activated) activator | 0.131 0.035 DBMET00330 | DBMET00330 | |
| 0.006 | 0.428 | 0.094 | Liver X receptor alpha antagonist | 0.094 0.004 DBMET00330 | DBMET00330 | |
| 0.041 | 0.476 | 0.103 | Transcription factor STAT6 inhibitor | 0.103 0.1 DBMET00330 | DBMET00330 | |
| 0.014 | 0.453 | 0.171 | Alkylator | 0.171 0.037 DBMET00330 | DBMET00330 | |
| 0.017 | 0.457 | 0.082 | Caspase 7 inhibitor | 0.082 0.056 DBMET00330 | DBMET00330 | |
| 0.062 | 0.527 | 0.369 | Vasodilator, peripheral | 0.369 0.066 DBMET00330 | DBMET00330 | |
| 0.015 | 0.481 | 0.192 | Psychostimulant | 0.192 0.085 DBMET00330 | DBMET00330 | |
| 0.028 | 0.495 | 0.062 | Heme oxygenase stimulant | 0.062 0.041 DBMET00330 | DBMET00330 | |
| 0.006 | 0.477 | 0.103 | Glutamate receptor agonist | 0.103 0.035 DBMET00330 | DBMET00330 | |
| 0.014 | 0.491 | 0.085 | Topoisomerase I inhibitor | 0.085 0.084 DBMET00330 | DBMET00330 | |
| 0.003 | 0.483 | 0.032 | HCV NS5B polymerase inhibitor | 0.032 0.021 DBMET00330 | DBMET00330 | |
| 0.026 | 0.506 | 0.207 | Cell wall synthesis inhibitor | 0.207 0.027 DBMET00330 | DBMET00330 | |
| 0.053 | 0.538 | 0.277 | Gastrin inhibitor | 0.277 0.051 DBMET00330 | DBMET00330 | |
| 0.022 | 0.521 | 0.227 | Immunostimulant | 0.227 0.106 DBMET00330 | DBMET00330 | |
| 0.023 | 0.524 | 0.129 | Interleukin 8 antagonist | 0.129 0.051 DBMET00330 | DBMET00330 | |
| 0.018 | 0.521 | 0.119 | AMP-activated protein kinase stimulant | 0.119 0.049 DBMET00330 | DBMET00330 | |
| 0.044 | 0.548 | 0.184 | Neuropeptide Y2 antagonist | 0.184 0.151 DBMET00330 | DBMET00330 | |
| 0.03 | 0.535 | 0.162 | Hemostatic | 0.162 0.055 DBMET00330 | DBMET00330 | |
| 0.053 | 0.568 | 0.254 | Vasodilator, coronary | 0.254 0.131 DBMET00330 | DBMET00330 | |
| 0.034 | 0.567 | 0.161 | Cyclic AMP phosphodiesterase inhibitor | 0.161 0.135 DBMET00330 | DBMET00330 | |
| 0.008 | 0.546 | 0.078 | Inducible nitric-oxide synthase inhibitor | 0.078 0.066 DBMET00330 | DBMET00330 | |
| 0.032 | 0.572 | 0.254 | Transcription factor NF kappa B inhibitor | 0.254 0.124 DBMET00330 | DBMET00330 | |
| 0.013 | 0.601 | 0.117 | Interleukin 1 beta converting enzyme inhibitor | 0.117 0.038 DBMET00330 | DBMET00330 | |
| 0.018 | 0.621 | 0.145 | DNA methyltransferase I inhibitor | 0.145 0.109 DBMET00330 | DBMET00330 | |
| 0.018 | 0.667 | 0.14 | DNA methylase inhibitor | 0.14 0.127 DBMET00330 | DBMET00330 | |
| 0.021 | 0.683 | 0.23 | DNA damaging | 0.23 0.093 DBMET00330 | DBMET00330 | |
| 0.006 | 0.669 | 0.034 | Tryptophan hydroxylase 1 inhibitor | 0.034 0.003 DBMET00330 | DBMET00330 | |
| 0.004 | 0.758 | 0.142 | Diuretic | 0.142 0.084 DBMET00330 | DBMET00330 | |
| 0.015 | 0.782 | 0.227 | Hypoxia-inducible factor 1 alpha inhibitor | 0.227 0.122 DBMET00330 | DBMET00330 | |
| 0.005 | 0.788 | 0.053 | Guanylate cyclase stimulant | 0.053 0.018 DBMET00330 | DBMET00330 | |
| 0.002 | 0.801 | 0.06 | Free fatty acid receptor 1 agonist | 0.06 0.004 DBMET00330 | DBMET00330 | |
| 0.002 | 0.849 | 0.014 | Thyroid hormone alpha antagonist | 0.014 0.013 DBMET00330 | DBMET00330 | |
| 0.002 | 0.866 | 0.159 | Prostaglandin D2 antagonist | 0.159 0.004 DBMET00330 | DBMET00330 | |
| 0.004 | 0.869 | 0.035 | Glutamate (mGluR group II) agonist | 0.035 0.024 DBMET00330 | DBMET00330 | |
| 0.002 | 0.877 | 0.042 | Retinoid X gamma receptor antagonist | 0.042 0.004 DBMET00330 | DBMET00330 | |
| 0.003 | 0.95 | 0.027 | Purinergic P2Y14 antagonist | 0.027 0.026 DBMET00330 | DBMET00330 | |
| 0.005 | 0.969 | 0.442 | Antiinflammatory | 0.442 0.114 DBMET00330 | DBMET00330 | |
| 0.003 | 0.969 | 0.216 | Prostaglandin antagonist | 0.216 0.006 DBMET00330 | DBMET00330 | |
| 0.024 | 0.995 | 0.328 | Calcium channel L-type activator | 0.328 0.134 DBMET00330 | DBMET00330 | |
| 0.006 | 0.978 | 0.629 | Apoptosis antagonist | 0.629 0.007 DBMET00330 | DBMET00330 | |
| 0.002 | 0.974 | 0.134 | Diacylglycerol O-acyltransferase 1 inhibitor | 0.134 0.004 DBMET00330 | DBMET00330 | |
| 0 | 0.979 | 0.007 | Phosphoribosylglycinamide formyltransferase inhibitor | 0.007 0.006 DBMET00330 | DBMET00330 | |
| 0.003 | 0.988 | 0.067 | Elastase inhibitor | 0.067 0.024 DBMET00330 | DBMET00330 | |
| 0.002 | 0.987 | 0.122 | Peroxisome proliferator-activated receptor delta antagonist | 0.122 0.005 DBMET00330 | DBMET00330 | |
| 0.009 | 0.996 | 0.234 | Lipocortins synthesis antagonist | 0.234 0.039 DBMET00330 | DBMET00330 | |
| 0.003 | 0.993 | 0.044 | VCAM-1 antagonist | 0.044 0.016 DBMET00330 | DBMET00330 | |
| 0.003 | 0.993 | 0.044 | VCAM antagonist | 0.044 0.016 DBMET00330 | DBMET00330 | |
| 0.001 | 0.991 | 0.023 | Retinoic acid alpha receptor antagonist | 0.023 0.011 DBMET00330 | DBMET00330 | |
| 0.007 | 0.999 | 0.21 | Peptidyltransferase inhibitor | 0.21 0.087 DBMET00330 | DBMET00330 | |
| 0.003 | 0.996 | 0.068 | Glutamate (mGluR8) antagonist | 0.068 0.004 DBMET00330 | DBMET00330 | |
| 0.001 | 0.993 | 0.022 | Integrin beta7 antagonist | 0.022 0.012 DBMET00330 | DBMET00330 | |
| 0.003 | 0.997 | 0.084 | Caspase 9 inhibitor | 0.084 0.02 DBMET00330 | DBMET00330 | |
| 0.002 | 0.996 | 0.104 | Nitric oxide donor | 0.104 0.007 DBMET00330 | DBMET00330 | |
| 0.003 | 0.997 | 0.107 | DNA helicase inhibitor | 0.107 0.005 DBMET00330 | DBMET00330 | |
| 0.003 | 0.996 | 0.07 | Potassium channel large-conductance Ca-activated activator | 0.07 0.044 DBMET00330 | DBMET00330 | |
| 0.002 | 0.996 | 0.338 | Hypolipemic | 0.338 0.038 DBMET00330 | DBMET00330 | |
| 0.002 | 0.996 | 0.098 | Prostaglandin F2 alpha antagonist | 0.098 0.012 DBMET00330 | DBMET00330 | |
| 0.002 | 0.997 | 0.333 | Amyloid beta aggregation inhibitor | 0.333 0.039 DBMET00330 | DBMET00330 | |
| 0.004 | 0.999 | 0.348 | Interleukin 2 agonist | 0.348 0.046 DBMET00330 | DBMET00330 | |
| 0.003 | 0.997 | 0.058 | Adenine nucleotide translocase inhibitor | 0.058 0.032 DBMET00330 | DBMET00330 | |
| 0.002 | 0.997 | 0.543 | Hypoglycemic | 0.543 0.012 DBMET00330 | DBMET00330 | |
| 0.001 | 0.996 | 0.037 | AMPA receptor agonist | 0.037 0.021 DBMET00330 | DBMET00330 | |
| 0.001 | 0.995 | 0.047 | Retinoid X beta receptor agonist | 0.047 0.005 DBMET00330 | DBMET00330 | |
| 0.001 | 0.995 | 0.02 | Retinoic acid receptor antagonist | 0.02 0.012 DBMET00330 | DBMET00330 | |
| 0.002 | 0.996 | 0.108 | Sphingosine 1-phosphate receptor 5 agonist | 0.108 0.007 DBMET00330 | DBMET00330 | |
| 0.001 | 0.996 | 0.038 | Erythropoietin receptor agonist | 0.038 0.03 DBMET00330 | DBMET00330 | |
| 0.001 | 0.996 | 0.036 | Integrin alpha4beta7 antagonist | 0.036 0.007 DBMET00330 | DBMET00330 | |
| 0.001 | 0.996 | 0.037 | Protocollagen prolyl hydroxylase inhibitor | 0.037 0.009 DBMET00330 | DBMET00330 | |
| 0.002 | 0.997 | 0.273 | MAP3K9 inhibitor | 0.273 0.004 DBMET00330 | DBMET00330 | |
| 0.002 | 0.997 | 0.208 | P-glycoprotein inhibitor | 0.208 0.059 DBMET00330 | DBMET00330 | |
| 0.001 | 0.996 | 0.058 | VLA-4 antagonist | 0.058 0.011 DBMET00330 | DBMET00330 | |
| 0.002 | 0.997 | 0.197 | Cell adhesion inhibitor | 0.197 0.026 DBMET00330 | DBMET00330 | |
| 0.002 | 0.997 | 0.258 | Platelet antagonist | 0.258 0.069 DBMET00330 | DBMET00330 | |
| 0.001 | 0.997 | 0.085 | Plasminogen activator inhibitor antagonist | 0.085 0.014 DBMET00330 | DBMET00330 | |
| 0.001 | 0.997 | 0.047 | Retinoic acid alpha receptor agonist | 0.047 0.017 DBMET00330 | DBMET00330 | |
| 0.002 | 0.998 | 0.382 | Immunosuppressant | 0.382 0.071 DBMET00330 | DBMET00330 | |
| 0.001 | 0.997 | 0.16 | Aldose reductase inhibitor | 0.16 0.01 DBMET00330 | DBMET00330 | |
| 0.001 | 0.997 | 0.08 | Leukotriene synthesis inhibitor | 0.08 0.038 DBMET00330 | DBMET00330 | |
| 0.002 | 0.998 | 0.305 | Hepatoprotectant | 0.305 0.028 DBMET00330 | DBMET00330 | |
| 0.001 | 0.997 | 0.118 | Integrin antagonist | 0.118 0.014 DBMET00330 | DBMET00330 | |
| 0.001 | 0.997 | 0.047 | Prostaglandin D2 agonist | 0.047 0.009 DBMET00330 | DBMET00330 | |
| 0.001 | 0.997 | 0.167 | Peroxisome proliferator-activated receptor gamma agonist | 0.167 0.009 DBMET00330 | DBMET00330 | |
| 0.001 | 0.997 | 0.057 | Integrin alpha4 antagonist | 0.057 0.01 DBMET00330 | DBMET00330 | |
| 0.001 | 0.997 | 0.055 | p53 inhibitor | 0.055 0.011 DBMET00330 | DBMET00330 | |
| 0.001 | 0.997 | 0.04 | HMG CoA reductase inhibitor | 0.04 0.015 DBMET00330 | DBMET00330 | |
| 0.001 | 0.997 | 0.028 | Vitronectin receptor antagonist | 0.028 0.011 DBMET00330 | DBMET00330 | |
| 0.001 | 0.997 | 0.046 | Retinoid X gamma receptor agonist | 0.046 0.006 DBMET00330 | DBMET00330 | |
| 0.001 | 0.997 | 0.017 | Integrin beta6 antagonist | 0.017 0.005 DBMET00330 | DBMET00330 | |
| 0.001 | 0.997 | 0.072 | Prostacyclin antagonist | 0.072 0.007 DBMET00330 | DBMET00330 | |
| 0.002 | 0.998 | 0.049 | Integrin alpha1beta1 antagonist | 0.049 0.008 DBMET00330 | DBMET00330 | |
| 0 | 0.997 | 0.022 | Prostacyclin agonist | 0.022 0.008 DBMET00330 | DBMET00330 | |
| 0.001 | 0.997 | 0.024 | Leukotriene B4 receptor 1 antagonist | 0.024 0.023 DBMET00330 | DBMET00330 | |
| 0.001 | 0.998 | 0.174 | Insulin secretagoues | 0.174 0.052 DBMET00330 | DBMET00330 | |
| 0.001 | 0.998 | 0.278 | Nitric oxide antagonist | 0.278 0.045 DBMET00330 | DBMET00330 | |
| 0.001 | 0.998 | 0.125 | Uric acid excretion stimulant | 0.125 0.035 DBMET00330 | DBMET00330 | |
| 0.001 | 0.998 | 0.113 | Prostaglandin EP2 antagonist | 0.113 0.016 DBMET00330 | DBMET00330 | |
| 0.001 | 0.998 | 0.086 | HIV-1 integrase inhibitor | 0.086 0.034 DBMET00330 | DBMET00330 | |
| 0.001 | 0.998 | 0.238 | Thrombolytic | 0.238 0.037 DBMET00330 | DBMET00330 | |
| 0 | 0.998 | 0.048 | Complement C3a chemotactic receptor antagonist | 0.048 0.028 DBMET00330 | DBMET00330 | |
| 0.001 | 0.998 | 0.133 | Cell adhesion molecule inhibitor | 0.133 0.019 DBMET00330 | DBMET00330 | |
| 0.001 | 0.998 | 0.027 | Integrin alphaVbeta1 antagonist | 0.027 0.007 DBMET00330 | DBMET00330 | |
| 0.001 | 0.998 | 0.022 | Retinoic acid gamma receptor agonist | 0.022 0.017 DBMET00330 | DBMET00330 | |
| 0 | 0.998 | 0.023 | Integrin beta5 antagonist | 0.023 0.012 DBMET00330 | DBMET00330 | |
| 0.002 | 0.999 | 0.139 | Growth hormone agonist | 0.139 0.097 DBMET00330 | DBMET00330 | |
| 0.001 | 0.998 | 0.039 | Macrophage elastase inhibitor | 0.039 0.034 DBMET00330 | DBMET00330 | |
| 0.001 | 0.999 | 0.355 | Sodium/bile acid cotransporter inhibitor | 0.355 0.037 DBMET00330 | DBMET00330 | |
| 0 | 0.998 | 0.041 | Squalene synthetase inhibitor | 0.041 0.018 DBMET00330 | DBMET00330 | |
| 0.001 | 0.999 | 0.101 | Folate antagonist | 0.101 0.063 DBMET00330 | DBMET00330 | |
| 0.001 | 0.999 | 0.145 | Angiogenesis stimulant | 0.145 0.126 DBMET00330 | DBMET00330 | |
| 0.001 | 0.998 | 0.043 | Integrin alpha5beta1 antagonist | 0.043 0.025 DBMET00330 | DBMET00330 | |
| 0 | 0.998 | 0.025 | Integrin alphaVbeta3 antagonist | 0.025 0.012 DBMET00330 | DBMET00330 | |
| 0 | 0.999 | 0.053 | Angiotensin-converting enzyme inhibitor | 0.053 0.04 DBMET00330 | DBMET00330 | |
| 0 | 0.999 | 0.055 | GP IIb/IIIa receptor antagonist | 0.055 0.03 DBMET00330 | DBMET00330 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |